The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
Open accessAbstract
OBJECTIVE: To compare effects of combinations of standard and intensive treatment of glycemia and either blood pressure (BP) or lipids in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: ACCORD enrolled 10,251 type 2 diabetes patients aged 40–79 years at high risk for cardiovascular disease (CVD) events. Participants were randomly assigned to hemoglobin A1c goals of <6.0% (<42 mmol/mol; intensive glycemia) or 7.0–7.9% (53–63 mmol/mol; standard glycemia) and then randomized a second time to either 1) systolic BP goals of <120 mmHg (intensive BP) or <140 mmHg (standard BP) or 2) simvastatin plus fenofibrate (intensive lipid) or simvastatin plus placebo (standard lipid). Proportional hazards models were used to assess combinations of treatment assignments on the composite primary (deaths due to CVD, nonfatal myocardial infarction [MI], and nonfatal stroke) and secondary outcomes. RESULTS: In the BP trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [HR] 0.67; 95% CI 0.50–0.91), BP (HR 0.74; 95% CI 0.55–1.00), or both (HR 0.71; 95% CI 0.52–0.96) compared with combined standard BP and glycemia treatment. For secondary outcomes, MI was significantly reduced by intensive glycemia treatment and stroke by intensive BP treatment; most other HRs were neutral or favored intensive treatment groups. In the lipid trial, the general pattern of results showed no evidence of benefit of intensive regimens (whether single or combined) compared with combined standard lipid and glycemia treatment. The mortality HR was 1.33 (95% CI 1.02–1.74) in the standard lipid/intensive glycemia group compared with the standard lipid/standard glycemia group. CONCLUSIONS: In the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, SBP >140 mmHg or <120 mmHg were related to higher risk of adverse renal outcomes in patients with diabetes when compared with those without diabetes and with high CV risk.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“and dysglycemia, high blood pressure (BP), and dyslipidemia mediate much of this increased CVD risk (1).”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“The Steno-2 study showed a major reduction in CVD events and mortality with multifactorial intensive treatment (5,6).”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
The global epidemiology of hypertension
Mills, K. T., Stefanescu, A., & He, J. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0244-2 · Cited by 4,133
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.06.010 · Cited by 947
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 920
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000597 · Cited by 902
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
Bundy, J. D., Li, C., Stuchlik, P., Bu, X., Kelly, T. N., Mills, K. T., He, H., Chen, J., Whelton, P. K., & He, J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1421 · Cited by 783
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Hypertension Across a Woman’s Life Cycle
Wenger, N. K., Arnold, A., Bairey Merz, C. N., Cooper-DeHoff, R. M., Ferdinand, K. C., Fleg, J. L., Gulati, M., Isiadinso, I., Itchhaporia, D., Light-McGroary, K., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.033 · Cited by 298
Diabetes and peripheral artery disease: A review
Soyoye, D. O., Abiodun, O. O., Ikem, R. T., Kolawole, B. A., & Akintomide, A. O. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.827 · Cited by 272
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 169
Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160151 · Cited by 228
The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
Hannon, T. S., & Arslanian, S. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12939 · Cited by 137
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2017) · Diabetes Care · doi:10.2337/dc17-1366 · Cited by 120
Wright, A. K., Suárez‐Ortegón, M. F., Read, S. H., Kontopantelis, E., Buchan, I. E., Emsley, R., Sattar, N. A., Ashcroft, D. M., Wild, S. H., & Rutter, M. K. (2020) · Circulation · doi:10.1161/circulationaha.120.046783 · Cited by 125
Upadhya, B., Rocco, M., Lewis, C. E., Oparil, S., Lovato, L. C., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G., Fine, L. J., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003613 · Cited by 118
Self-citation(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Beddhu, S., Chertow, G. M., Greene, T., Whelton, P. K., Ambrosius, W. T., Cheung, A. K., Cutler, J. A., Fine, L. J., Boucher, R. E., Wei, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009326 · Cited by 121
Self-citationDiabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Bigeh, A., Sanchez, A. M., Maestas, C. M., & Gulati, M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.10.001 · Cited by 117
Goodenough, C. J., Liang, M. K., Nguyen, M. T., Nguyen, D. H., Holihan, J. L., Alawadi, Z. M., Roth, J. S., Wray, C. J., Ko, T. C., & Kao, L. S. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.07.013 · Cited by 109
On the utilization of polygenic risk scores for therapeutic targeting
Gibson, G. C. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008060 · Cited by 107
Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells
Lee, Y., Berglund, E. D., Yu, X., Wang, M.-Y., Evans, M. R., Scherer, P. E., Holland, W. L., Charron, M. J., Roth, M. G., & Unger, R. H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409638111 · Cited by 103
SPRINT Trial Results: Latest News in Hypertension Management
Cushman, W. C., Whelton, P. K., Fine, L. J., Wright, J. T., Reboussin, D. M., Johnson, K., & Oparil, S. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06722 · Cited by 93
Self-citationWeber, T., Lang, I. M., Zweiker, R., Horn, S., Wenzel, R. R., Watschinger, B., Slany, J., Eber, B., Roithinger, F. X., & Metzler, B. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0998-5 · Cited by 101
Chung, Y.-R., Park, S. W., Choi, S.-Y., Kim, S. W., Moon, K. Y., Kim, J. H., & Lee, K. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0486-2 · Cited by 85
Bress, A. P., King, J. B., Kreider, K. E., Beddhu, S., Simmons, D. L., Cheung, A. K., Zhang, Y., Doumas, M. N., Nord, J. W., Sweeney, M. E., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0885 · Cited by 84
Self-citationType 2 diabetes in Brazil: epidemiology and management
Eliaschewitz, F. G., de Almeida-Pititto, B., Rodrigues, M. L. D., de Moraes, A. C. F., Ferreira, S. R. G., & Franco, D. R. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s72542 · Cited by 93
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Muntner, P., Whelton, P. K., Woodward, M., & Carey, R. M. (2018) · Diabetes Care · doi:10.2337/dc18-1307 · Cited by 70
Tan, S. M. Q., Chiew, Y., Ahmad, B., & Kadir, K. A. (2018) · Nutrients · doi:10.3390/nu10091315 · Cited by 68
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 106
Chiang, C., Wang, T., Lin, T., Yeh, H., Liu, P., Cheng, H., Chao, T., Chen, C., Shyu, K., Ueng, K.-C., et al. (2017) · Europe PMC (PubMed Central) · doi:10.6515/acs20170421a · Cited by 59
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 68
Women, Hypertension, and the Systolic Blood Pressure Intervention Trial
WENGER, N. K., Ferdinand, K. C., Merz, C. N. B., Walsh, M. N., Gulati, M., & Pepine, C. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.022 · Cited by 59
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Imprialos, K. P., Boutari, C., Stavropoulos, K., Doumas, M. N., & Karagiannis, A. I. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314704 · Cited by 59
Rašković, A., Ćućuz, V., Torović, L. D., Tomás, A., Gojković‐Bukarica, L., Ćebović, T. N., Milijašević, B., Stilinović, N., & Cvejić, J. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.08.006 · Cited by 58
Zhu, L., Hayen, A. D., & Bell, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01002-x · Cited by 60
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 63
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 64
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 52
Cunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Van Tassell, B. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13248 · Cited by 42
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 44
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 41
Capítulo 3 - Avaliação Clínica e Complementar
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160153 · Cited by 51
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 46
Tsujimoto, T., & Kajio, H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11408 · Cited by 38
Managing Hypertension in the elderly: What’s new?
Aronow, W. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100001 · Cited by 41
Capítulo 14 – Crise Hipertensiva
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160164 · Cited by 33
Shen, Y. H., Dai, Y., Wang, X. Q., Zhang, R., Lu, L., Ding, F. H., & Shen, W. F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0959-1 · Cited by 39
Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care
Derington, C. G., King, J. B., Bryant, K. B., McGee, B. T., Moran, A. E., Weintraub, W. S., Bellows, B. K., & Bress, A. P. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0996-x · Cited by 32
Curovic, V. R., Hansen, T. W., Eickhoff, M. K., von Scholten, B. J., Reinhard, H., Jacobsen, P. K., Persson, F., Parving, H., & Rossing, P. R. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1205-0 · Cited by 31
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Kimando, M. W., Otieno, F. C. F., Ogola, E. N., & Mutai, K. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0223-1 · Cited by 28
Management of hypertension in patients with chronic kidney disease
Hamrahian, S. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0739-9 · Cited by 26
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Saha, S., Fang, X., Green, C. D., & Das, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015078 · Cited by 26
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease
Habiba, U. E., Khan, N., Greene, D. L., Shamim, S., & Umer, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02432-w · Cited by 27
Tian, J., Sheng, C., Sun, W., Song, X., Wang, H., Li, Q., Li, W., & Wang, W. (2018) · Diabetes Care · doi:10.2337/dc18-0918 · Cited by 28
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
Mancia, G., & Grassi, G. M. (2018) · Diabetologia · doi:10.1007/s00125-017-4537-3 · Cited by 26
Oparil, S., & Lewis, C. E. (2016) · Circulation · doi:10.1161/circulationaha.116.023263 · Cited by 24
Gosmanov, A. R., Lü, J., Sumida, K., Potukuchi, P. K., Rhee, C. M., Kalantar‐Zadeh, K., Molnar, M. Z., & Kovesdy, C. P. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000864 · Cited by 25
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Recommendations for Intensive Blood Pressure Lowering in High-Risk Patients, the Canadian Viewpoint
Padwal, R. S., Rabi, D. M., & Schiffrin, E. L. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07573 · Cited by 23
Capítulo 9 - Hipertensão Arterial na gestação
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Poli‐de‐Figueiredo, C. E., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160159 · Cited by 60
Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?
Grassi, G. M., Mancia, G., & Nilsson, P. M. (2016) · Diabetes Care · doi:10.2337/dcs15-3020 · Cited by 26
Control of blood pressure and cardiovascular outcomes in type 2 diabetes
Vargas‐Uricoechea, H., & Cáceres-Acosta, M. F. (2018) · Open Medicine · doi:10.1515/med-2018-0048 · Cited by 31
White, W. B., Jalil, F., Cushman, W. C., Bakris, G. L., Bergenstal, R., Heller, S. R., Liu, Y., Mehta, C., Zannad, F., & Cannon, C. P. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009114 · Cited by 22
Self-citationUmbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 22
Approaches for the Management of Resistant Hypertension in 2020
Aronow, W. S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-019-1013-0 · Cited by 23
Hypertension in diabetes care: emerging roles of recent hypoglycemic agents
Tanaka, A., & Node, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00665-7 · Cited by 21
Strelitz, J., Ahern, A. L., Long, G. H., Boothby, C. E., Wareham, N. J., & Griffin, S. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0902-5 · Cited by 21
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway
Arad, M., Waldman, M., Abraham, N. G., & Hochhauser, E. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106454 · Cited by 21
Cloutier, L., & Lamarre-Cliché, M. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.01.012 · Cited by 22
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Song, D. K., Hong, Y. S., Sung, Y., & Lee, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299035 · Cited by 22
Zanchi, A., Jehle, A. W., Lamine, F., Vogt, B., Czerlau, C., Bilz, S., Seeger, H., & de Seigneux, S. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40004 · Cited by 21
Hypertension up to date: SPRINT to SPYRAL
Kulenthiran, S., Ewen, S., Böhm, M., & Mahfoud, F. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1095-0 · Cited by 20
Impact of the SPRINT Trial on Hypertension Management
Ghazi, L., & Oparil, S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050416-024516 · Cited by 20
Targeting blood pressure for stroke prevention: current evidence and unanswered questions
Béjot, Y. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09443-5 · Cited by 18
Kim, H., Kim, H. M., Kwon, C. H., Shin, J., Jung, M., Lee, C. J., Kim, D., Kim, W.-H., Kang, S., Lee, J., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01156-8 · Cited by 19
Metadata
- Authors
- Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., Lipkin, E. W., Narayan, K. M. V., Riddle, M. C., Sood, A., & Goff, D. C.
- Affiliations
- HealthPartners (US)
- Wake Forest University Health Sciences (US)
- University of North Carolina at Chapel Hill (US)
- Cincinnati VA Medical Center (US)
- Memphis VA Medical Center (US)
- National Heart, Lung, and Blood Institute (US)
- McMaster University (CA)
- Berman Center for Outcomes and Clinical Research (US)
- University of Washington (US)
- Emory University (US)
- Oregon Health & Science University (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Colorado School of Public Health (US)
- Corresponding author
- Margolis, Karen L.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1721-1728
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4030092
- OpenAlex
- W2167872811
- Cited by
- 259
- References
- 29
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 19 · 2019: 31 · 2018: 54 · 2017: 32 · 2016: 39 · 2015: 7 · 2014: 5
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- type 2 diabetes, cardiovascular risk management, tight glycemic control, HbA1c, blood pressure control, lipid-lowering therapy, simvastatin, fenofibrate, cardiovascular outcomes, myocardial infarction, stroke, mortality, ACCORD trial, combination therapy, cardiovascular risk reduction, high-risk patients, secondary prevention, primary prevention, cardiovascular risk stratification
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Myocardial Infarction, Outcome and Process Assessment, Health Care, Fenofibrate, Risk Factors, Disease Management, Simvastatin, Stroke, Risk Reduction Behavior, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.